Reply to thread

Message: [QUOTE="DocStressor, post: 3876493, member: 10851"] That figure is from the Jansan/J&J slide presentation to the FDA. [URL]https://www.fda.gov/media/146265/download[/URL] It indicates the occurrence of severe disease which is defined as: Case Definition for Severe/Critical COVID-19 Positive PCV Test plus: ≥ 1 of these signs or symptoms Clinical signs indicative of severe systemic illness: Respiratory rate ≥ 30 bpm, heart rate ≥ 125 bpm, SpO2 ≤ 93% on room air at sea level or PaO2/FiO2 < 300 mmHg Respiratory failure: Needing high-flow oxygen, non-invasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation [ECMO] Evidence of shock: Systolic blood pressure < 90 mmHg, diastolic blood pressure < 60 mmHg, or requiring vasopressors Significant acute renal, hepatic, or neurologic dysfunction It does not include data from mild or moderate infections. While it may suggest to people unfamiliar with interpreting this kind of data that protection is >90% and continues to increase with time, you can't conclude that. If you look at the cumulative incidence data on pg 37 of the report you will see that the number of people included at the later dates is very low. Hence the large confidence interval. It is a good vaccine that demonstrated 100% protection from hospitalization and death after day 28 in the trials. But it is not as effective in protecting against mild to moderate COVID-19 as the mRNA vaccines. They are testing the efficacy of a 2 dose regime now. It is likely that a second dose with a variant viral sequence will be available by winter. This will be the case for the mRNA vaccines as well. I would not hesitate getting the J&J vaccine now if it is available. [/QUOTE]

Verification: First name of men's bb coach

Forum statistics

Threads: 164,478

Messages: 4,397,759

Members: 10,211

Latest member: MurrDog